Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in moderately to severely active UC in a Phase 3 trial Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in infl…
Merck's Tulisokibart successfully met primary and key secondary endpoints in its Phase 3 ATLAS-UC induction-only study for moderately to severely active Ulcerative Colitis. This makes it the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in…
Market Samachar is a news aggregator. This article was originally published by Merck.com. Tap the button above to read the full story on their site.